Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 3, 2012, Pages 802-808

  Butelman, Eduardo R ^a   Caspers, Michael ^b   Lovell, Kimberly M ^b   Kreek, Mary Jeanne ^a   Prisinzano, Thomas E ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; LOPERAMIDE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; PSYCHEDELIC AGENT; SALVINORIN A; TARIQUIDAR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG POTENTIATION; ENZYME SUBSTRATE; FEMALE; IN VIVO STUDY; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PTOSIS; SENSITIVITY ANALYSIS;

ANIMALS; BLEPHAROPTOSIS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DISCRIMINATION (PSYCHOLOGY); DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; FACIAL MUSCLES; FEMALE; HALLUCINOGENS; LOPERAMIDE; MACACA MULATTA; MALE; P-GLYCOPROTEINS; QUINOLINES; RECEPTORS, OPIOID, KAPPA; SALVIA;

EID: 84861569915     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.193227     Document Type: Article

References (39)

1. Bankstahl JP, Bankstahl M, Kuntner C, Stanek J, Wanek T, Meier M, Ding XQ, Müller M, Langer O, and Löscher W (2011) A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci 31:8803-8811.
2. Bauer M, Karch R, Neumann F, Wagner CC, Kletter K, Müller M, Löscher W, Zeitlinger M, and Langer O (2010) Assessment of regional differences in tariquidar- induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab 30:510-515.
3. Butelman ER, Harris TJ, and Kreek MJ (1999) Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys. Psychopharmacology (Berl) 147:73-80. (Pubitemid 30010026)
4. Butelman ER, Mandau M, Tidgewell K, Prisinzano TE, Yuferov V, and Kreek MJ (2007) Effects of salvinorin A, a κ-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high κ-receptor homology to humans. J Pharmacol Exp Ther 320:300-306. (Pubitemid 46025744)
5. Butelman ER, Prisinzano TE, Deng H, Rus S, and Kreek MJ (2009) Unconditioned behavioral effects of the powerful κ-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther 328:588-597.
6. Butelman ER, Reed B, Chait BT, Mandau M, Yuferov V, and Kreek MJ (2008) Limited effects of β endorphin compared to loperamide or fentanyl in a neuroendocrine biomarker assay in non-human primates. Psychoneuroendocrinology 33: 292-304. (Pubitemid 351249101)
7. Butelman ER, Rus S, Prisinzano TE, and Kreek MJ (2010) The discriminative effects of the κ-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects. Psychopharmacology (Berl) 210:253-262.
8. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, and Roth BL (2004) Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious κ-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 308:1197-1203. (Pubitemid 38263998)
9. Dagenais C, Graff CL, and Pollack GM (2004) Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269-276. (Pubitemid 38112757)
10. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165-174. (Pubitemid 40023528)
11. Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, and Fowler JS (2008) Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage 41:1044-1050.
12. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
13. Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, and Griffiths RR (2011) Human psychopharmacology and dose-effects of salvinorin A, a κ opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115: 150-155.
14. Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, Herscovitch P, Pike VW, and Innis RB (2010) P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethylloperamide. J Nucl Med 51:559-566.
15. Kurdziel KA, Kiesewetter DO, Carson RE, Eckelman WC, and Herscovitch P (2003) Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J Nucl Med 44:1330-1339. (Pubitemid 39655194)
16. Lange JE, Daniel J, Homer K, Reed MB, and Clapp JD (2010) Salvia divinorum: effects and use among YouTube users. Drug Alcohol Depend 108:138-140.
17. Levran O, O'Hara K, Peles E, Li D, Barral S, Ray B, Borg L, Ott J, Adelson M, and Kreek MJ (2008) ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 17:2219-2227. (Pubitemid 351916578)
18. Lin JH (2008) CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 9:46-59.
19. Lin JH and Yamazaki M (2003) Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35:417-454. (Pubitemid 38018115)
20. Liow JS, Kreisl W, Zoghbi SS, Lazarova N, Seneca N, Gladding RL, Taku A, Herscovitch P, Pike VW, and Innis RB (2009) P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med 50:108-115.
21. Lipman B, Palmer D, Noble J, Haughton V, and Collier D (1988) Effect of lumbar puncture on flow of cerebrospinal fluid. Invest Radiol 23:359-360.
22. Liu-Chen LY (2004) Agonist-induced regulation and trafficking of κ opioid receptors. Life Sci 75:511-536.
23. Moons T, de Roo M, Claes S, and Dom G (2011) Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12:1193-1211.
24. Namanja HA, Emmert D, Davis DA, Campos C, Miller DS, Hrycyna CA, and Chmielewski J (2012) Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. J Am Chem Soc 134:2976-2980.
25. O'Brien FE, Dinan TG, Griffin BT, and Cryan JF (2012) Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 165:289-312
26. Przekop P and Lee T (2009) Persistent psychosis associated with Salvia divinorum use. Am J Psychiatry 166:832.
27. Robey RW, Massey PR, Amiri-Kordestani L, and Bates SE (2010) ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem 10:625-633.
28. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, and Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous κ opioid selective agonist. Proc Natl Acad Sci U S A 99:11934-11939. (Pubitemid 34994502)
29. Schmidt MD, Schmidt MS, Butelman ER, Harding WW, Tidgewell K, Murry DJ, Kreek MJ, and Prisinzano TE (2005) Pharmacokinetics of the plant-derived κ-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 58:208-210. (Pubitemid 41443741)
30. Siebert DJ (2010) Localization of salvinorin A and related compounds in glandular trichomes of the psychoactive sage, Salvia divinorum. Ann Bot 93:763-771.
31. Singh S (2007) Adolescent salvia substance abuse. Addiction 102:823-824.
32. Teksin ZS, Lee IJ, Nemieboka NN, Othman AA, Upreti VV, Hassan HE, Syed SS, Prisinzano TE, and Eddington ND (2009) Evaluation of the transport, in vitro metabolism and pharmacokinetics of salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm 72:471-477.
33. Ur E, Wright DM, Bouloux PM, and Grossman A (1997) The effects of spiradoline (U-62066E), a κ-opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol 120:781-784. (Pubitemid 27122716)
34. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, et al. (2012) Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135:181-189.
35. Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, Kletter K, Löscher W, Müller M, Zeitlinger M, et al. (2009) A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med 50:1954-1961.
36. Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY, Huang P, Li JG, Cowan A, and Liu-Chen LY (2005) Comparison of pharmacological activities of three distinct κ ligands (Salvinorin A, TRK-820 and 3FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312:220-230. (Pubitemid 40096472)
37. Wilson-Pauwels L, Stewart PA, Akesson EJ, and Spacey SD (2010) Cranial Nerves: Function and Dysfunction. People's Medical Publishing House, Shelton, CT.
38. Zoghbi SS, Liow JS, Yasuno F, Hong J, Tuan E, Lazarova N, Gladding RL, Pike VW, and Innis RB (2008) 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 49:649-656. (Pubitemid 351520614)
39. Zolnerciks JK, Booth-Genthe CL, Gupta A, Harris J, and Unadkat JD (2011) Substrate- and species-dependent inhibition of P-glycoprotein-mediated transport: implications for predicting in vivo drug interactions. J Pharm Sci 100: 3055-3061.